Nestlé Health Science announced that it will make an equity investment of $145m in US-based Aimmune Therapeutics, which corresponds to a 15% stake after completion of the transaction. The parties also entered into a strategic ...
Tags: Food Allergies, Nestle
DBV Technologies, creator of Viaskin, has entered into a collaboration agreement with BioNet-Asia and the University of Geneva (UNIGE) to work on a whooping cough (pertussis) booster vaccine. The clinical proof of concept product ...
Tags: DBV Technologies, Booster Vaccine
France-based biopharmaceutical firms Stallergenes and DBV Technologies have entered into a research and development agreement for the treatment of birch allergy. Stallergenes is specialized in the manufacturing of immunotherapy medicines ...
DBV Technologies and Stallergenes have entered into a strategic research partnership to develop immunotherapy treatments for respiratory allergies using DBV's skin patch, Viaskin. The collaboration combines Stallergenes' know-how in ...